Clinical Trials | June 16, 2026
Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
